- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07590843
Efficacy and Safety of a Novel Monopolar Radiofrequency Device for Mid and Lower Face Rejuvenation
Efficacy and Safety of a Novel Monopolar Radiofrequency Device for Mid and Lower Face Rejuvenation: A Retrospective Pre-Post Comparative Study
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Aging of the face progresses through complex structural changes, including a decrease in skin elasticity, collagen loss, changes in subcutaneous fat distribution, and relaxation of the superficial musculoaponeurotic system (SMAS). These changes are particularly prominent in the mid and lower face, which has led to the widespread use of non-invasive energy-based lifting and contouring procedures in cosmetic and dermatology clinical practices.
Traditional laser and high-output radiofrequency (RF) based lifting treatments generally deliver brief high-temperature energy (over 70°C) to tissues, inducing protein denaturation and coagulation, followed by collagen remodeling through the wound healing process to achieve long-term effects. Although these treatments can induce relatively rapid clinical changes, side effects such as pain during the procedure, as well as erythema, edema, and blisters, which are associated with thermal damage, have been reported.
To address these limitations, there has been increasing interest in low-temperature-maintaining RF treatments that minimize tissue degeneration while inducing biological responses. In particular, RF stimulation in the range of 43-45°C is known to be a temperature range that does not induce tissue coagulation and is believed to trigger reactions related to cellular metabolic activation and programmed cell death (apoptosis), rather than necrosis-based damage with accompanying acute inflammatory responses. This approach has advantages, including relatively less pain, shorter recovery times, and the possibility of repeated treatments.
Recent studies have also reported that TRPV1 receptors, activated by thermal stimulation above 43°C, may be associated not only with pain transmission but also with the activation of fibroblasts, regulation of collagen and extracellular matrix (ECM) synthesis, and regulation of adipocyte metabolism. Some experimental studies have observed an increase in fibroblast proliferation and ECM production when RF energy was applied to maintain a temperature range of 43-45°C for a certain period. However, this evidence has been largely limited to studies focusing on the skin layer, and there is still limited systematic human research on the clinical efficacy and safety of RF treatments that simultaneously stimulate both the skin and subcutaneous fat layers.
NeoSculpt is a monopolar RF system designed with a multi-channel handpiece structure using different frequencies (1 MHz and 2 MHz) to deliver energy progressively to the dermal-SMAS interface and subcutaneous fat layers. Through a low-temperature-maintaining RF protocol, it is expected to achieve mid- and lower-face lifting and contouring effects. However, objective data regarding the efficacy, safety, and clinical changes associated with the use of this device in actual clinical settings are not yet sufficiently accumulated.
This study aims to evaluate the clinical outcomes of mid- and lower-face lifting and contouring treatments using the NeoSculpt monopolar RF device through a retrospective pre-post comparative analysis utilizing existing clinical records.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Sydkorea, 13620
- Seoul National University Bundang Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Adult patients who have undergone mid- and lower-face lifting and contouring treatments using NeoSculpt RF
- Cases where pre- and post-treatment evaluation data are available after completing 3 sessions
Exclusion Criteria:
- Missing key evaluation data
- Cases where follow-up observations were not conducted after treatment
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
20 patients
This study is an observational, retrospective cohort study.
Considering the number of patients available at a single institution and the feasibility of the study, a total of 20 participants were selected.
This is considered the minimum number of subjects required to perform the pre-post comparative analysis planned in this study and to assess the clinical trends and safety of mid- and lower-face lifting and contouring treatments.
In this study, personally identifiable information (such as name, resident registration number, etc.) will not be collected, and research data will be anonymized and analyzed using a study ID number.
All data will be managed by the principal investigator, and use for purposes other than the research is restricted.
|
This is a retrospective observational study analyzing existing medical records of patients who received NeoSculpt monopolar radiofrequency treatment as part of routine clinical care at a private dermatology clinic.
The investigator did not assign or administer any intervention as part of this study.
All clinical photographs, 3D photographic assessments, and ultrasound measurements were obtained during routine clinical visits prior to study initiation.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Clinician-Assessed Improvement in Standardized Clinical Photographs
Tidsram: baseline, 1month, 2month, 3month, 6month
|
Two blinded dermatologists independently evaluate standardized clinical photographs taken before and after treatment.
Improvement is rated on a 5-point scale (0 = no improvement, 1 = minimal improvement [1-25%], 2 = moderate improvement [26-50%], 3 = marked improvement [51-75%], 4 = excellent improvement [>75%]).
Higher scores indicate greater improvement.
|
baseline, 1month, 2month, 3month, 6month
|
|
Change in Mid- and Lower-Face Volume Measured by 3D Photographic System
Tidsram: Baseline, Month 1, Month 2, Month 3, Month 6
|
Facial volume in the mid-cheek, jawline, and nasolabial fold regions is measured using a 3D photographic system.
Change from baseline is reported in cubic millimeters (mm³).
|
Baseline, Month 1, Month 2, Month 3, Month 6
|
|
Change in Skin Layer Collagen Thickness Measured by Ultrasound
Tidsram: Baseline, Month 1, Month 2, Month 3, Month 6
|
Collagen thickness of the dermal layer is measured using high-frequency ultrasound imaging.
Change from baseline is reported in millimeters (mm).
|
Baseline, Month 1, Month 2, Month 3, Month 6
|
|
Change in SMAS-Adjacent Adipose Tissue Thickness Measured by Ultrasound
Tidsram: Baseline, Month 1, Month 2, Month 3, Month 6
|
Thickness of adipose tissue adjacent to the superficial musculoaponeurotic system (SMAS) is measured using high-frequency ultrasound imaging.
Change from baseline is reported in millimeters (mm).
|
Baseline, Month 1, Month 2, Month 3, Month 6
|
|
Investigator Global Assessment (IGA) Score for Overall Facial Improvement
Tidsram: Baseline, Month 1, Month 2, Month 3, Month 6
|
Three independent, blinded dermatologists evaluate overall facial improvement using the Investigator Global Assessment (IGA) scale.
Scores range from 0 to 4 (0 = no improvement, 1 = minimal improvement [1-25%], 2 = moderate improvement [26-50%], 3 = marked improvement [51-75%], 4 = excellent improvement [>75%]).
Higher scores indicate greater improvement.
The mean score across three evaluators is reported.
|
Baseline, Month 1, Month 2, Month 3, Month 6
|
|
Incidence of Treatment-Emergent Adverse Events
Tidsram: baseline, 1month, 2month, 3month, 6month
|
|
baseline, 1month, 2month, 3month, 6month
|
|
Duration and Resolution of Adverse Events
Tidsram: Month 1, Month 2, Month 3, Month 6
|
Description: For participants who experience adverse events, the duration (in days) from onset to resolution is recorded. Clinical course and any management performed are documented at each follow-up visit. Unit of Measure: Days |
Month 1, Month 2, Month 3, Month 6
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Patient-Reported Pain Score During Treatment
Tidsram: Month 1, Month 2, Month 3
|
Patients rate procedural pain using a numeric rating scale from 0 to 10 (0 = no pain, 10 = worst imaginable pain).
Higher scores indicate greater pain intensity.
|
Month 1, Month 2, Month 3
|
|
Patient-Reported Overall Satisfaction Score
Tidsram: Month 1, Month 2, Month 3, Month 6
|
Patients rate overall satisfaction with treatment outcome using a numeric rating scale from 0 to 10 (0 = completely dissatisfied, 10 = completely satisfied).
Higher scores indicate greater satisfaction.
|
Month 1, Month 2, Month 3, Month 6
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- NeoSculpt_SNUBH
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .